Qi-Ying Hu

This inventor holds 33 USPTO granted patents and 18 published patent applications, plus 4 CIPO patents and 13 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Novartis Ag, Decibel Therapeutics, Inc., Glaxosmithkline Biologicals Sa. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Qi-Ying Hu. Retrieved from https://idiyas.com/inventor/qi-ying-hu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 18)

% Patents Active = 66.7

CIPO Patents = 4 (Patent Applications = 6)

EPO Patents = 13 (Patent Applications = 24)

Average Co-Inventor Count = 3.3

ph-index = 4

Forward Citations = 93(Granted Patents)

Location History:

Cambrdige, MA (US) (2015)
Cambridge, MA (US) (2013 - 2021)
Needham, MA (US) (2011 - 2024)

Company Filing History:

Decibel Therapeutics, Inc.

patents

2 out of 545

Glaxosmithkline Biologicals Sa

patents

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

Otoprotection

Platinum-Based Agents

Synthetic Apelin Mimetics

Aldosterone Synthase

Conjugation Methods

Organic Compounds

Hypertonic Compositions

Tyrosine Ligation

Disulfide Proteins

Cycloalkyne Derivatives

Pharmaceutical Compositions

Heart Failure Treatment

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12653838 - Methods of otoprotection against platinum-based antineoplastic agents (2026-06-16),

2. 12409231 - Cycloalkyne derivatized saccharides (2025-09-09),

3. 11857567 - Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent (2024-01-02),

4. 11690870 - Methods of otoprotection against platinum-based antineoplastic agents (2023-07-04),

5. 11311400 - Methods for making conjugates from disulfide-containing proteins (2022-04-26),

6. 11135300 - Cycloalkyne derivatized saccharides (2021-10-05),

7. 11071751 - Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent (2021-07-27),

8. 10813947 - Methods of otoprotection against platinum-based antineoplastic agents (2020-10-27),

9. 10709732 - Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent (2020-07-14),

10. 10667935 - Methods for making conjugates from disulfide-containing proteins (2020-06-02),

11. 10406198 - Methods for making conjugates from disulfide-containing proteins (2019-09-10),

12. 10172948 - Methods for oxime conjugation to ketone-modified polypeptides (2019-01-08),

13. 10022256 - Methods for making conjugates from disulfide-containing proteins (2018-07-17),

14. 9982017 - Synthetic apelin mimetics for the treatment of heart failure (2018-05-29),

15. 9434754 - Use of an adrenal hormone-modifying agent (2016-09-06),

Title: Innovations and Contributions of Qi-Ying Hu in Pharmaceutical Patents

Introduction

Qi-Ying Hu, based in Needham, MA, has made significant strides in the field of pharmaceutical innovations, holding a remarkable total of 31 patents. His work focuses on developing novel methods and compositions aimed at improving patient outcomes during chemotherapy treatments, particularly regarding the use of platinum-based antineoplastic agents.

Latest Patents

Among his latest contributions are two noteworthy patents. The first patent outlines hypertonic pharmaceutical compositions that contain an anti-platinum chemoprotectant agent and a gelling agent. This innovative composition aims to provide protective benefits to patients undergoing treatments with platinum compounds. The second patent presents methods of otoprotection, detailing the administration of a thiosulfate salt to protect against the ototoxic effects of platinum-based antineoplastic agents. This method specifies important timelines for administration, ensuring maximum efficacy and safety for patients.

Career Highlights

Qi-Ying Hu has had a fruitful career with significant roles at esteemed organizations, including Novartis AG and Decibel Therapeutics, Inc. His experience in these prominent companies has provided him with the expertise required to innovate in the biopharmaceutical sector.

Collaborations

Throughout his career, Qi-Ying has collaborated with notable professionals such as Julien Papillon and Hidetomo Imase. These partnerships illustrate his ability to work with talented individuals in the scientific community to advance his research and patent applications.

Conclusion

In conclusion, Qi-Ying Hu's contributions to the field of pharmaceuticals through his patents illustrate his profound impact on improving cancer treatments and protecting patients from adverse effects. His dedication to innovation continues to pave the way for advancements in therapeutic options for those undergoing chemotherapy.

Profile summary based on public USPTO records.